Investor Interest in Dividend Stocks: In uncertain market conditions, investors are increasingly drawn to dividend-yielding stocks, which typically feature companies with strong free cash flows that provide high dividend payouts.
Pfizer Inc Updates: Pfizer has a dividend yield of 6.67%. Recent analyst ratings include an Equal-Weight rating from Morgan Stanley with a price target cut to $32, and a Neutral rating from B of A Securities with a price target raised to $30. Pfizer recently completed its acquisition of Metsera, Inc.
DENTSPLY SIRONA Inc Ratings: DENTSPLY SIRONA has a dividend yield of 5.84%. Analyst Brandon Vazquez downgraded the stock to Market Perform, while UBS maintained a Buy rating but lowered the price target to $23. The company reported weaker-than-expected earnings and lowered guidance.
Viatris Inc Performance: Viatris has a dividend yield of 4.40%. Goldman Sachs initiated coverage with a Neutral rating and a $10 price target, while Piper Sandler reiterated a Neutral rating and also cut the price target to $10. Viatris reported better-than-expected quarterly earnings recently.
Wall Street analysts forecast VTRS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for VTRS is 11.00 USD with a low forecast of 9.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast VTRS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for VTRS is 11.00 USD with a low forecast of 9.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
3 Hold
1 Sell
Hold
Current: 13.370
Low
9.00
Averages
11.00
High
14.00
Current: 13.370
Low
9.00
Averages
11.00
High
14.00
Truist
Les Sulewski
Buy
maintain
$15 -> $16
Al Analysis
2026-01-07
Reason
Truist
Les Sulewski
Price Target
$15 -> $16
Al Analysis
2026-01-07
maintain
Buy
Reason
Truist analyst Les Sulewski raised the firm's price target on Viatris to $16 from $15 and keeps a Buy rating on the shares. The affordable medicines theme remains attractive heading into 2026, the analyst tells investors in a research note.
Wedbush
Laura Chico
Neutral
maintain
$23 -> $33
2025-12-11
Reason
Wedbush
Laura Chico
Price Target
$23 -> $33
2025-12-11
maintain
Neutral
Reason
Wedbush analyst Laura Chico raised the firm's price target on Vera Therapeutics to $33 from $23 and keeps a Neutral rating on the shares. The firm notes the company completed an upsized $261M secondary offering. The deal included issuance of 6.1M shares of common stock at $42.50/share. The offering also incorporated an overallotment of 921k additional shares. Assuming exercise of the shoe, Wedbush estimates the offering will generate $281M in net proceeds. The firm's prior estimates assumed a later offering of similar magnitude.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for VTRS
Unlock Now
Evercore ISI
Gavin Clark-Gartner
Outperform
maintain
$75 -> $97
2025-12-08
Reason
Evercore ISI
Gavin Clark-Gartner
Price Target
$75 -> $97
2025-12-08
maintain
Outperform
Reason
Evercore ISI analyst Gavin Clark-Gartner raised the firm's price target on Vera Therapeutics to $97 from $75 and keeps an Outperform rating on the shares. Voyxact's pricing at $30,000 per vial, totaling $390,000 annually, exceeds investor expectations and the firm's updated IgAN market model now forecasts $12.5B in peak worldwide sales, with $9.4B from the U.S. alone, the analyst says.
Barclays
Glen Santangelo
Overweight
initiated
$15
2025-12-08
Reason
Barclays
Glen Santangelo
Price Target
$15
2025-12-08
initiated
Overweight
Reason
Barclays analyst Glen Santangelo initiated coverage of Viatris with an Overweight rating and $15 price target. The firm rolled out coverage on the specialty pharmaceuticals industry with a neutral view, saying investor sentiment is improving as companies shift focus to innovation, margin expansion and de-leveraging. The group's pricing headwinds are easing while debt leverage is coming down, the analyst tells investors in a research note. Barclays sees "plenty of opportunity" as the sector "remains in a transition phase."
About VTRS
Viatris Inc. is a global healthcare company. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in China, Taiwan and Hong Kong. The JANZ segment reflects its operations in Japan, Australia, and New Zealand. The Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies, including in Asia, Africa, Eastern Europe, Latin America, and the Middle East, as well as the Company’s Antiretroviral medicines (ARV) franchise. Its pipeline and research and development capabilities include expertise in formulation, device development, toxicology, analytical, clinical, bioanalytical, medical affairs, product safety and risk management across a range of therapeutic areas. It produces oral solid doses, injectables, and products with complex dosage forms.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
